1. Home
  2. GAU vs BWAY Comparison

GAU vs BWAY Comparison

Compare GAU & BWAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Galiano Gold Inc.

GAU

Galiano Gold Inc.

HOLD

Current Price

$2.05

Market Cap

606.0M

Sector

N/A

ML Signal

HOLD

Logo BrainsWay Ltd.

BWAY

BrainsWay Ltd.

HOLD

Current Price

$14.43

Market Cap

572.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GAU
BWAY
Founded
1999
2003
Country
Canada
Israel
Employees
N/A
129
Industry
Medical/Dental Instruments
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
606.0M
572.1M
IPO Year
2006
N/A

Fundamental Metrics

Financial Performance
Metric
GAU
BWAY
Price
$2.05
$14.43
Analyst Decision
Buy
Strong Buy
Analyst Count
2
2
Target Price
$4.08
$13.25
AVG Volume (30 Days)
2.7M
147.7K
Earning Date
05-13-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$82.77
$309.69
Revenue Next Year
$29.09
$26.21
P/E Ratio
N/A
$81.98
Revenue Growth
N/A
N/A
52 Week Low
$1.22
$10.65
52 Week High
$3.62
$26.63

Technical Indicators

Market Signals
Indicator
GAU
BWAY
Relative Strength Index (RSI) 35.73 43.22
Support Level $1.96 $11.90
Resistance Level $2.74 $14.65
Average True Range (ATR) 0.10 0.54
MACD -0.02 -0.13
Stochastic Oscillator 19.68 32.42

Price Performance

Historical Comparison
GAU
BWAY

About GAU Galiano Gold Inc.

Galiano Gold Inc is focused on building a sustainable business capable of long term value creation for its stakeholders through a combination of exploration, accretive acquisitions, and disciplined deployment of its financial resources. The company currently operates and manages: Nkran, Esaase, Abore and Miradani North, multiple satellite deposits and exploration projects located on the Asankrangwa Gold Belt in the Amansie West District of the Republic of Ghana (Ghana), West Africa.

About BWAY BrainsWay Ltd.

BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.

Share on Social Networks: